BBH Review gives students a platform to research, write, and publish thoughtful perspectives on the business, policy, and innovation shaping the future of healthcare.
This project explores how manufacturing capacity became a competitive weapon in the booming GLP-1 market. It examines how supply strategy, not just innovation, reshaped the race between industry leaders and determined who could actually meet unprecedented patient demand.
Health Tech
This project evaluates how AI-driven prediction models can more accurately estimate surgical duration, a key driver of operating room efficiency. It highlights how better forecasting improves scheduling, reduces costly OR downtime, and streamlines hospital workflows for both staff and patients.
This project analyzes why the U.S. healthcare system continues to underperform compared to peer nations despite spending significantly more per capita. It breaks down the structural drivers behind this paradox and what they reveal about the gap between healthcare spending and health outcomes.
Policy
By Nitya Jhamb & Smiraa Misra
Why do three insulin makers and a single EpiPen supplier get to set life-or-death prices? How patents and “evergreening” sustain pharma monopolies, and what reform could change.
Biotech
By Elizabeth Gagea & Emma Lee
Inside Nurix’s DELigase platform, and how targeted protein degradation aims to turn the cell’s own disposal system into a weapon against cancer.
Policy
By Jessica Wang
The Inflation Reduction Act lets Medicare negotiate drug prices for the first time. Who benefits, who’s suing to stop it, and how it could reshape pharma.
Policy
By Elysse Mendoza
As California opens Medi-Cal to more low-income adults, a look at the economics, politics, and equity questions behind the push for single-payer care.
Careers
By Star Yu
Want startup experience? A roundup of open biotech and biopharma internships, from patient-research firms to AI-driven drug discovery.
Innovation
By Tia Ketsan
Seventeen people die each day waiting for organs. Genetically modified pig hearts and kidneys could change that, if the science and public trust can catch up.
Biotech
By Hassanali Bhimji, Marco Chamorro & Tina Su
From telomeres to senescent cells to Bryan Johnson’s $2M-a-year Blueprint, the science and business racing to slow, or reverse, human aging.
Business
By Isabela Ramirez & Armaan Salahuddin
Cost Plus Drugs cuts out pharmacy benefit managers to sell generics at a flat 15% markup. Can one disruptor actually reset how drugs are priced?
Policy
By Aatmi Mehta & Star Yu
An aging population, retiring nurses, and strained schools are driving a national nursing shortage, with staffing, not pay, at the center of the fight.
Innovation
By Renga Rengappa
The pandemic made telehealth mainstream. Where care-from-home stands now on coverage, cross-state licensing, and the digital divide.